ArticleInfluenza and other respiratory viruses2020
Approaches to use the WHO respiratory syncytial virus surveillance platform to estimate disease burden.
Article in Influenza and other respiratory viruses, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Disease burden due to respiratory syncytial virus infection among under-5 children of India for 2020: a multiplicative model using meta-estimates.BMJ global health · 2025Pooled it
- Review
- A strategic blueprint for strengthening respiratory syncytial virus prevention among under-five children in low- and middle-income countries: Bangladesh as a model for new immunisation approaches.Journal of global health · 2026Article
- Respiratory syncytial virus-attributable hospitalizations among adults in high- and middle-income countries: application of the Global Burden of Disease framework.EClinicalMedicine · 2025Article
- Review
- Multiple merger coalescent inference of effective population size.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
- Molecular epidemiology of influenza, respiratory syncytial virus, SARS-CoV-2, other respiratory viruses and bacteria among children 0-2-year-olds in West Bengal: a one-year influenza-like illness surveillance study (2022-2023).Frontiers in epidemiology · 2025Article
- Respiratory syncytial virus prophylaxis for children in Africa: Challenges, opportunities and public health strategies.Journal of public health in Africa · 2025Article
- Review
- RSV Infection in Refugees and Asylum Seekers: A Systematic Review and Meta-Analysis.Epidemiologia (Basel, Switzerland) · 2024Review
- Review
- Characteristics of clinical trials of influenza and respiratory syncytial virus registered in ClinicalTrials.gov between 2014 and 2021.Frontiers in public health · 2023Article
- Responding to Higher-Than-Expected Infant Mortality Rates from Respiratory Syncytial Virus (RSV): Improving Treatment and Reporting Strategies.Infection and drug resistance · 2023Review
- RSV disease in infants and young children: Can we see a brighter future?Human vaccines & immunotherapeutics · 2022Article
- Respiratory Syncytial Virus: New Challenges for Molecular Epidemiology Surveillance and Vaccination Strategy in Patients with ILI/SARI.Vaccines · 2021Article
- Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication.Scientific reports · 2021Article
- Mortality From Respiratory Syncytial Virus in Children Under 2 Years of Age: A Prospective Community Cohort Study in Rural Maharashtra, India.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Respiratory Syncytial Virus-Associated Mortality Among Young Infants in Karachi, Pakistan: A Prospective Postmortem Surveillance Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Recommendations for respiratory syncytial virus surveillance at the national level.The European respiratory journal · 2021Article
- Evaluation of a standardised protocol to measure the disease burden of respiratory syncytial virus infection in young children in primary care.BMC infectious diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The World Health Organization (WHO) recently completed the first phase of a RSV surveillance pilot study in fourteen countries (two to three in each WHO region) building on the Global Influenza Surveillance and Response System (GISRS). This active surveillance strategy had several objectives including understanding RSV-related health burden in a variety of settings. A range of approaches can be used to estimate disease burden; most approaches could not be applied by participating countries in the WHO surveillance pilot. This article provides the recommendations made by WHO for strengthening and expanding the scope of the RSV surveillance in the next phase to enable burden estimation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.